AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie is favored over Bristol Myers Squibb for 2026, supported by FY2025 revenue growth of 8.6% to $61.2B, $17.8B in free cash flow, and expanding immunology franchises including Skyrizi and Rinvoq. BMY generated $48.2B of revenue, down 0.2%, but delivered a stronger 14.6% net margin and trades at a substantially cheaper 9.2x forward P/E versus AbbVie's 18.5x. The article argues AbbVie's Humira erosion is largely behind it, while BMY still faces legacy-product patent risks, execution uncertainty, and a revived $6.7B Celgene acquisition lawsuit.

Analysis

The relevant distinction is not growth versus value, but earnings-duration certainty. ABBV's premium requires continued upside revisions from its post-Humira franchises while preserving pricing and formulary access; a merely in-line outlook would likely compress the multiple even if absolute earnings rise. BMY's discount already prices a prolonged loss-of-exclusivity valley, so incremental evidence that newer products can offset erosion should produce disproportionate equity upside through both estimate revision and multiple normalization.

Wholesaler concentration is less a credit issue than a gross-to-net and inventory-timing issue for ABBV: MCK, COR, and CAH possess limited ability to alter end demand, but channel inventory movements, rebate negotiations, and payer-driven formulary shifts can make quarterly sell-in volatile. Those distributors are more likely neutral-to-positive second-order beneficiaries if specialty-drug volumes rise, although their economics are determined more by service fees and working capital than drug list-price growth.

The consensus framing appears too favorable to ABBV's visibility and too dismissive of BMY's optionality. ABBV has already rerated on successful execution, leaving less room for a positive surprise; BMY needs only stabilization in the legacy-product decline and credible growth-brand uptake to challenge the current valuation gap. Over the next 1-3 months, earnings guidance, prescription-volume trends, and any update on litigation reserves are the key catalysts; over 6-18 months, Medicare pricing implementation and exclusivity-related revenue erosion determine whether either multiple is sustainable.

Key Decisions for Investors

• Initiate a 3-6 month market-neutral pair: long BMY / short ABBV in equal dollar amounts, entered in tranches around the next earnings releases. The setup monetizes valuation convergence if BMY guides to a manageable revenue trough or ABBV's growth guidance merely holds; exit if BMY cuts growth-brand or cash-flow guidance, or if ABBV delivers another material full-year earnings raise.
• For long-only healthcare exposure, do not chase ABBV solely on franchise momentum. Maintain a neutral weight until prescription-share data and management guidance demonstrate that growth is exceeding payer-rebate pressure; a deceleration in net sales growth without a corresponding cost-offset program is the primary multiple-compression risk.
• Treat BMY as a catalyst watch rather than an unhedged value purchase until the expected cash impact and timing of the Celgene litigation are independently quantified. Add to the long leg only if legal reserves remain contained and management confirms that dividend coverage and debt reduction are not being subordinated to acquisition spending.
• Keep MCK and COR on a watchlist as lower-beta specialty-pharma volume proxies rather than direct ABBV beneficiaries. A sustained acceleration in immunology and oncology script volumes could support earnings through distribution throughput, but require quarterly evidence of specialty-services margin expansion before initiating positions.